# Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus

> **NCT04240171** · — · COMPLETED · sponsor: **Damanhour University** · enrollment: 60 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin 5Mg Tab
- **DRUG:** Glimepiride 4Mg Tab

## Key facts

- **NCT ID:** NCT04240171
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-01-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04240171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04240171, "Dapagliflozin Versus Glimepiride Effect in Patient With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04240171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*